Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D Utility Scores

References

• Tosh JC, Longworth LJ, George E. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. Value Health: J Int Soc Pharmacoeconom Outcomes Res 2011;14:102–109
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008
   Google Scholar
• Longworth L, Rowen D. NICE DSU technical support document 10: the use of mapping methods to estimate health state utility values. London: NICE, 2011
   Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615–625
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Mieler WF, Grassi M, et al. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol 2008;92:89–92
   PubMed Web of Science ®Google Scholar
• Klein R, Moss SE, Klein BE, et al. The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol 2001;119:733–740
   PubMedGoogle Scholar
• Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119:1050–1058
   PubMed Web of Science ®Google Scholar
• Payakachat N, Summers KH, Pleil AM, et al. Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration. Qual Life Res 2009;18:801–813
   Google Scholar
• The National Eye Institute. 25-Item Visual Function Questionnaire (VFQ-25).Version 2000. Available at: http://www.rand.org/content/dam/rand/www/external/health/surveys_tools/vfq/vfq25_manual.pdf. Accessed 4 April 2012
   Google Scholar
• EuroQol – a new facility for the measurement of health-related quality of life. Health Policy: EuroQoL, 1990. Available from: http://www.euroqol.org (Accessed 2 November 2012)
   Google Scholar
• EuroQol Group. EQ-5D User guide: Basic information on how to use EQ-5D, version 2.0, March 2009. Available at: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/User_Guide_v2_March_2009.pdf. Accessed 2 November 2012
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–1108
   PubMed Web of Science ®Google Scholar
• Pullenayegum EM, Tarride JE, Xie F, et al. Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate? Value Health 2010;13:487–494
   PubMed Web of Science ®Google Scholar
• Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003;157:364--375
   PubMed Web of Science ®Google Scholar
• Huang IC, Frangakis C, Atkinson MJ, et al. Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res 2008;43:327–339
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340–349
   PubMed Web of Science ®Google Scholar
• Bharmal M, Thomas J 3rd. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 2006;9:262–271
   PubMed Web of Science ®Google Scholar
• Dakin H, Gray A, Murray D. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Qual Life Res 2013;22:683--694
   Google Scholar
• Saarni SI, Suvisaari J, Sintonen H, et al. The health-related quality-of-life impact of chronic conditions varied with age in general population. J Clin Epidemiol 2007;60:1288–1297
   PubMed Web of Science ®Google Scholar
• Fenwick EK, Xie J, Ratcliffe J, et al. The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Invest Ophthalmol Vis Sci 2012;53:677–684
   PubMed Web of Science ®Google Scholar
• Lloyd AJ, Loftus J, Turner M, et al. Psychometric validation of the Visual Function Questionnaire-25 in patients with diabetic macular edema. Health Qual Life Outcomes 2013;11:10
   Google Scholar
• Bozzani FM, Alavi Y, Jofre-Bonet M, Kuper H. A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma. BMC Ophthalmol 2012;12:43
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM, Sharma S. Value-based medicine: evidence-based medicine and beyond. Ocul Immunol Inflamm 2003;11:157–170
   PubMed Web of Science ®Google Scholar
• Chuang LH, Kind P. Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies. PharmacoEconomics 2009;27:491–505
   Google Scholar
• Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. Value Health 2011;14:354–360
   PubMed Web of Science ®Google Scholar
• Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decision Making 2006;26:18–29
   PubMed Web of Science ®Google Scholar
• Rivero-Arias O, Ouellet M, Gray A, et al. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decision Making 2010;30:341–354
   PubMed Web of Science ®Google Scholar